Adapalene gel 0.3% for the treatment of acne vulgaris: a multicenter, randomized, double-blind, controlled, phase III trial

J Am Acad Dermatol. 2006 Feb;54(2):242-50. doi: 10.1016/j.jaad.2004.10.879.

Abstract

Background: A new 0.3% gel formulation of adapalene has been developed.

Objective: We sought to provide evidence of the superiority of adapalene gel 0.3% over adapalene gel 0.1% and gel vehicle in the treatment of acne.

Methods: A total of 653 patients were randomized to receive adapalene gel 0.3%, adapalene gel 0.1%, or vehicle once daily for 12 weeks (2:2:1 randomization). Analysis for efficacy was conducted on correlated repeated measurements at weeks 8 and 12 using Generalized Estimating Equation methodology.

Results: Adapalene gel 0.3% was significantly superior to adapalene gel 0.1% and vehicle in success rate, total lesion count, and inflammatory lesion count. A consistent, dose-dependent effect was demonstrated for all efficacy measures. Signs and symptoms were mostly mild to moderate and transient in nature.

Limitations: Adjunctive topical or oral agents and their impact on acne were not studied in this trial.

Conclusions: Adapalene gel 0.3% was effective and well tolerated in the treatment of acne.

Publication types

  • Clinical Trial, Phase III
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acne Vulgaris / drug therapy*
  • Adapalene
  • Adolescent
  • Adult
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage*
  • Child
  • Dose-Response Relationship, Drug
  • Female
  • Gels
  • Humans
  • Male
  • Naphthalenes / administration & dosage*
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Gels
  • Naphthalenes
  • Adapalene